You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm reported selling more billable tests in Q1 than any previous quarter and said that it is starting to see momentum in new initiatives, such as carrier screening.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
Seventy-eight percent of participants had at least one positive carrier screening result and 3.5 percent had a medically actionable secondary finding.
The company delivered 4,621 billable tests during Q1, and billable testing volume was the highest in a quarter in Fulgent's history.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
Core Diagnostics will exclusively offer GenePeeks' preconception screen and advanced analytics platform in 29 states and seven territories in India.
The new deal, which covers Greece and Cyrus, follows a series of partnerships with fertility organizations and a separate distribution pact signed earlier this year.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.